Healthcare Business Recap: Vivus’s New Drug Available, Rosetta Shares Pop

Vivus, Inc. (NASDAQ:VVUS) shares moved up Monday following the firm’s disclosure in an 8-K with the Securities and Exchange Commission, and also on its website Qsymia.com, that its weight-loss drug Qsymia is available in the domestic market. Meanwhile, Vivus’ peer competitor Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) got a boost on the news as well, despite the fact that its own weight-loss drug, Belviq, will be unavailable until next year.

Don’t Miss: Lowe’s Will Not Be Expanding in Canada.

Danaher Corporation (NYSE:DHR) is buying IRIS International, Inc. (NASDAQ:IRIS) at $19.50 per share in a purchase comprised of cash and debt. The latter makes medical diagnostics equipment.

Shares of Rosetta Genomics Ltd. (NASDAQ:ROSG) popped Monday on word of its plans to release a business update through a conference call on October 2nd, just days prior to its annual meeting set for October 5th. Rosetta has jumped 56 percent over the past 30 days and 130 percent thus far in 2012.

Are these stocks a buy or sell? Let us help you decide. Check out our Wall St. Cheat Sheet Stock Picker Newsletter now >>